Essay: Inclusion of therapeutic failures as adverse drug reaction (K. Hartigan-Go, J.Q. Wong). 1. Central nervous system stimulants and drugs that suppress appetite (P. Sequeira). 2. Antidepressant drugs (P. Cowen). 3. Lithium (J. Jefferson). 4. Drugs of abuse (E.J. Wong, J.K. Patel and A.I. Green). 5. Hypnotics and sedatives ( S. Curran, S. Musa). 6. Neuroleptic and antipsychotic drugs ( A. Carvajal). 7. Antiepileptic drugs (E. Perucca). 8. Narcotic analgesics and antagonists (H. Ghodse, P.J. Bown). 9. Antipyretic analgesics, anti-inflammatory analgesics, and drugs used in gout (A. Del Favero). 10. General anesthetics and anesthetic gases (T. Short, C.N. Bradfield). 11. Local anesthetics (S. Schug). 12. Neuromuscular blocking agents and skeletal muscle relaxants (M.Leuwer). 13. Drugs affecting autonomic functions or the extrapyramidal system (M. Schachter). 14. Dermatological drugs, topical agents and cosmetics (P. Elsner et al.). 15. Antihistamines (H1-receptor antagonists) (D. Nicholson). 16. Drugs acting on the respiratory tract (J.W. Paterson). 17. Positive inotropic drugs and drugs used in dysrhythmias (J.K. Aronson). 18. Beta-adrenoceptor antagonists and antianginal drugs (A.P. Maggioni, M.G. Franziosi and R. Latini). 19. Drugs acting on the cerebral and peripheral circulations (R. Verhaeghe). 20. Antihypertensive drugs (F. Zannad). 21. Diuretics (G. McInnes). 22. Metals (G.B. van der Voet, F.A. De Wolff). 23. Metal antagonists (R.H.B. Meijboom). 24. Antiseptic drugs and disinfectants (P.Magee). 25. Penicillins, cephalosporins, other beta-lactam antibiotics, and tetracyclines (T. Midtvedt). 26. Miscellaneous antibiotics (R. Walter, A. Schaffner). 27. Antifungal drugs (C. Chiou, A. Groll, T.J. Walsh). 28. Antiprotozoal drugs (S. Krishna). 29. Antiviral drugs (P. Reiss, M.D. de Jong). 30. Drugs used in tuberculosis and leprosy (C.J. Ellis). 31. Antihelminthic drugs (A. Bauer). 32. Vaccines (S. Dittmann). 33. Blood, blood components, plasma, and plasma
The http://www.elsevier.com/locate/series/sedaSide Effects of Drugs Annual offers clinicians in areas as widespread as dermatology, neuroscience, endocrinology and many other medical disciplines a reliable and critical overview of all that is known in the area of Adverse Drugs Reactions.
An international team of specialists in the various areas have contributed to the current Annual. Particular attention is devoted to those publications providing essentially new information or throwing new light on problems already recognized. All that is truly new and informative (or points to what is misleading) is critically selected from the year's writing.
Every four years the previous set of four Annuals is summarised and evaluated, leading to the publication of the update of the major reference work, http://www.elsevier.com/locate/series/sedMeyler's Side Effects of Drugs. The /locate/isbn/0444500936Fourteenth updated Edition of Meyler's, published in December 2000, provides the reader with a summary of Side Effects of Drugs Annuals 20 - 23.
Clinical Pharmacologists, Medical Investigators, Clinicians, Pharmacists, Pharmacologists, Neuropharmacologists
- No. of pages:
- © Elsevier Science 2000
- 13th December 2000
- Elsevier Science
- eBook ISBN:
@from:A.P. Fletcher @qu:...As a reference book for those interested in adverse drug events/reactions (ADE/ADR) it is an essential addition to the library shelf and needs no further commendation. ...An interesting introductory 'Essay' Hartigan-Go and Wong makes a plea that therapeutic failure should be considered an ADR. ...Special reviews on current topics are identifiable by italic type and draw attention to new problems in ADR reporting. Dittmann's chapter on vaccines reviews the contentious issue of MMR vaccination, chronic inflammatory bowel disease and autism, which, at the time of this review, is still unresolved. @source:Adverse Drug Reactions and Toxicological Reviews @qu:...offers clinicians in areas as widespread as dermatology, neuroscience, endocrinology and many other medical disciplines a reliable and critical overview of all that is known in the area of Adverse Drug Reactions. @source:Journal of Investigational Allergology and Clinical Immunology
Dr Jeffrey K. Aronson is a consultant clinical pharmacologist and physician in the Department of Primary Health Care in the University of Oxford and a consultant physician in the Oxford Radcliffe Hospitals Trust. He has been associated with the Meyler series since 1977 and has published many research papers on adverse drug reactions. He is President of the British Pharmacological Society and serves on many committees concerned with drug therapy, including the Technology Appraisal Committee of the UK’s National Institute for Health and Clinical Excellence (NICE) and the Joint Formulary Committees of the British National Formulary and the British National Formulary for Children.
Department of Primary Health Care, University of Oxford, Oxford, UK